glp 1 agonists with cardiovascular benefit Frontiers GLP-1 Agonists in Cardiovascular Diseases:

Description

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

Laekna showcased LAE102 (ActRIIA antibody) for muscle regeneration and fat loss

Development of GLP-1MK-801 To safely harness the weight-lowering properties of NMDA receptor antagonism, we developed a targeting approach based on the hypothesis that conjugation of MK-801 to a GLP-1 analogue through a chemically cleavable disulfide linker would enhance the therapeutic potential of NMDA receptor antagonism in appetite-regulating brain regions enriched for GLP-1 receptors, while mitigating the adverse effects related to the non-restricted actions of MK-801